Allele and genotype frequencies of CYP2C9 in a Korean population
- PMID: 16187974
- PMCID: PMC1884827
- DOI: 10.1111/j.1365-2125.2005.02448.x
Allele and genotype frequencies of CYP2C9 in a Korean population
Abstract
Aims: To determine the frequencies of the variant alleles and the genotypes of CYP2C9 in a Korean population.
Methods: Three hundred and fifty-eight healthy Korean subjects were studied. CYP2C9 alleles were detected by polymerase chain reaction-restriction fragment length polymorphism assays and direct sequencing assays.
Results: The allele frequencies were 0.934 for CYP2C9*1, 0.060 for CYP2C9*3 and 0.006 for CYP2C9*13. The CYP2C9*2,*4,*5 and *11 alleles were not detected. The frequencies of the CYP2C9*1/*1, *1/*3 and *1/*13 genotypes were 0.869, 0.120 and 0.011, respectively.
Conclusion: The frequency of the CYP2C9*3 allele in the Korean population studied was significantly higher than reported elsewhere, and a novel allele, CYP2C9*13, was found at a frequency of 0.006 (95% confidence interval 0, 0.012). Only three genotypes of CYP2C9, CYP2C9*1/*1,*1/*3 and *1/*13 were observed in this Korean population.
Similar articles
-
Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics.Acta Pharmacol Sin. 2011 Oct;32(10):1303-8. doi: 10.1038/aps.2011.100. Epub 2011 Aug 15. Acta Pharmacol Sin. 2011. PMID: 21841812 Free PMC article.
-
Allele and genotype frequency of CYP2C9 in Tamilnadu population.Eur J Clin Pharmacol. 2003 Nov;59(8-9):707-9. doi: 10.1007/s00228-003-0666-3. Epub 2003 Sep 19. Eur J Clin Pharmacol. 2003. PMID: 14504850
-
Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.Br J Clin Pharmacol. 2002 Jun;53(6):596-603. doi: 10.1046/j.1365-2125.2002.01604.x. Br J Clin Pharmacol. 2002. PMID: 12047484 Free PMC article.
-
CYP2C9 allelic variants: ethnic distribution and functional significance.Adv Drug Deliv Rev. 2002 Nov 18;54(10):1257-70. doi: 10.1016/s0169-409x(02)00076-5. Adv Drug Deliv Rev. 2002. PMID: 12406644 Review.
-
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.Mol Diagn Ther. 2006;10(1):29-40. doi: 10.1007/BF03256440. Mol Diagn Ther. 2006. PMID: 16646575 Review.
Cited by
-
Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms.Pharmaceutics. 2022 Apr 1;14(4):771. doi: 10.3390/pharmaceutics14040771. Pharmaceutics. 2022. PMID: 35456605 Free PMC article.
-
CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide.Sci Rep. 2018 Jul 20;8(1):10994. doi: 10.1038/s41598-018-29351-4. Sci Rep. 2018. PMID: 30030468 Free PMC article.
-
Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population.BMC Res Notes. 2014 Mar 5;7:123. doi: 10.1186/1756-0500-7-123. BMC Res Notes. 2014. PMID: 24593903 Free PMC article.
-
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups.Pharmacogenomics. 2010 Jun;11(6):781-91. doi: 10.2217/pgs.10.49. Pharmacogenomics. 2010. PMID: 20504253 Free PMC article.
-
CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects.Eur J Clin Pharmacol. 2012 Feb;68(2):149-54. doi: 10.1007/s00228-011-1098-0. Epub 2011 Aug 13. Eur J Clin Pharmacol. 2012. PMID: 21842338 Clinical Trial.
References
-
- Schwarz UI. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. Eur J Clin Invest. 2003;33(Suppl. 2):23–30. - PubMed
-
- Ingelman-Sundberg M, Daly AK, Nebe DW, editors. [26 December 2004]. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web Site. Available from: http://www.imm.ki.se/CYPalleles/cyp2c9.htm.
-
- Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics. 2004;14:465–9. - PubMed
-
- Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717–9. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources